A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Canadian Myeloma Research Group
Canadian Myeloma Research Group
Celgene
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hadassah Medical Organization